Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|December 21, 2021
Pharmacy Clinical Pearl of the Day: Cold Sore
Author(s)Saro Arakelians, PharmD
Cold sores are usually caused by herpes simplex virus type 1 and herpes simplex virus type 2.
Advertisement
Clinical Pearl of the Day: Cold Sore
Cold sores, also called fever blisters, are a common viral infection.
Insight:
- Cold sores are tiny, fluid-filled blisters on and around your lips. These blisters are often grouped together in patches.
- After the blisters break, a scab forms that can last several days.
- Cold sores usually heal in 2 to 3 weeks without leaving a scar.
- Cold sores spread from person to person by close contact, such as kissing
- They're usually caused by herpes simplex virus type 1 and, less commonly, herpes simplex virus type 2.
- Symptoms include tingling, itching, blisters, oozing, and crusting.
- Treatment options may include acyclovir (Zovirax), valacyclovir (Valtrex), famciclovir, and penciclovir (Denavir).
- Other treatment options may include lip balms, applying cold compress, rest, and pain relievers.
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5